{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:26:04Z","timestamp":1791379564376,"version":"4.3.3"},"reference-count":8,"publisher":"MedWorks Media","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Introduction\nAlcoholic hallucinosis (AH) is one of the severe complications of chronic alcoholism, characterized by psychotic symptoms such as auditory hallucinations and delusions. Haloperidol is widely used to treat AH; however, its therapy is often complicated by side effects. A personalized approach using pharmacogenetic testing (particularly the CYP2D6 polymorphism) allows individualization of haloperidol dosage, improving both safety and efficacy of therapy.\nMaterials and Methods\nThe study included 100 men diagnosed with \u201cpsychotic disorder induced by alcohol use.\u201d Patients were randomized into two groups: the main group (45 patients) received haloperidol based on the results of pharmacogenetic testing, while the control group (55 patients) received standard dosing. Genotyping was conducted for the CYP2D6 1846G &gt; A polymorphism. The effectiveness was assessed using the PANSS, UKU, and SAS scales.\nResults\nGenotyping showed an even distribution of CYP2D6 polymorphisms in both groups. The main group demonstrated a significant reduction in side effects and improvement in psychotic symptoms compared to the control group. Differences on the UKU, SAS, and PANSS scales reached statistical significance on days 3\u20135 of treatment.\nConclusion\nUsing pharmacogenetic testing to adjust haloperidol dosage improves therapy tolerability and accelerates the resolution of psychotic symptoms in patients with alcoholic hallucinosis, confirming the feasibility of a personalized approach in psychopharmacotherapy.<\/jats:p>","DOI":"10.64719\/pb.4511","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"37-46","source":"Crossref","is-referenced-by-count":0,"title":["Use of a Personalized Clinical Decision Support System for Dosing in Psychopharmacotherapy in Patients with Alcoholic Hallucinosis Based on Pharmacogenomic Markers"],"prefix":"10.64719","volume":"55","author":[{"given":"VYu","family":"Skryabin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AE","family":"Petukhov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SA","family":"Pozdniakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"VA","family":"Ivanchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"IA","family":"Zaytsev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SS","family":"Miroshkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SI","family":"Sokolova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"IV","family":"Bure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"VV","family":"Smirnov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DA","family":"Sychev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Lepping P. Treatment of alcohol-induced psychotic disorder (Alcoholic Hallucinosis) Alcohol and Alcoholism. 2023;53(3):259\u2013264.","DOI":"10.1093\/alcalc\/agx090"},{"key":"ref2","unstructured":"Masood B, Poole R. Treatment of alcohol-induced psychotic disorder: A systematic review. Journal of Substance Use. 2018;23(1):47\u201356."},{"key":"ref3","unstructured":"Soyka M, Clausius N. Prevalence and treatment of alcoholic hallucinosis. Psychiatry Research. 2022;96(2):122\u2013128."},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Barkat M, Peter L, Dmitry R, Rob P. Treatment of alcohol-induced psychotic disorder (Alcoholic Hallucinosis)\u2014A systematic review. Alcohol and Alcoholism. 2021;53(3):259\u2013264.","DOI":"10.1093\/alcalc\/agx090"},{"key":"ref5","unstructured":"Cleveland Clinic. Haloperidol: Uses & side effects. Cleveland Clinic Health Library. 2024"},{"key":"ref6","unstructured":"Kato M, Serretti A. Pharmacogenetics of antipsychotic drugs: Focus on CYP2D6 and CYP2C19 polymorphisms. Pharmacogenomics Journal. 2022;22(1):31\u201342."},{"key":"ref7","unstructured":"Samara MT et al. Impact of CYP2D6 polymorphisms on haloperidol efficacy and tolerability. European Neuropsychopharmacology. 2021;31(7):427\u2013436."},{"key":"ref8","unstructured":"Stahl SM. Personalized prescribing of antipsychotics: The role of CYP2D6 and pharmacogenetic testing. CNS Spectrums. 2023;28(2):163\u2013169."}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:33:07Z","timestamp":1791315187000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/use-of-a-personalized-clinical-decision-support-system-for-dosing-in-psychopharmacotherapy-in-patients-with-alcoholic-hallucinosis-based-on-pharmacogenomic-markers\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":8,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4511","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}